Compare
Prokidney Corp. vs ImageneBio, Inc. vs Inhibrx Biosciences, Inc. vs Cardiff Oncology, Inc.
| Latest fiscal year | Prokidney Corp. PROK | ImageneBio, Inc. IMA | Inhibrx Biosciences, Inc. INBX | Cardiff Oncology, Inc. CRDF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $893.0K | $800.0K | $1.30M | $593.0K |
| Revenue growth (YoY) | n/m | -77.1% | +550.0% | -13.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$151.61M | -$45.35M | -$140.06M | -$45.85M |
| EPS (Diluted) | n/a | -$9.64 | -$9.04 | -$0.69 |
| Operating cash flow | -$120.12M | -$47.84M | -$129.79M | -$37.92M |
| Free cash flow | -$135.31M | n/a | -$129.82M | -$37.97M |
| Cash & equivalents | $108.54M | $94.53M | $124.22M | $17.47M |
| Total assets | $335.57M | $152.98M | $146.48M | $61.88M |
| Total liabilities | $34.78M | $19.84M | $138.49M | $16.50M |
| Shareholders' equity | -$1.01B | $133.14M | $7.99M | $45.39M |
| Return on year-end equity | n/a | -34.1% | n/m | -101.0% |
| Shares outstanding | n/a | n/a | 14.58M | 68.31M |
Revenue, most recent five fiscal years
| Fiscal year | Prokidney Corp. | ImageneBio, Inc. | Inhibrx Biosciences, Inc. | Cardiff Oncology, Inc. |
|---|---|---|---|---|
| Latest | $893.0K Ended 2025-12-31 | $800.0K Ended 2025-12-31 | $1.30M Ended 2025-12-31 | $593.0K Ended 2025-12-31 |
| 1 year earlier | $76.0K Ended 2024-12-31 | $3.50M Ended 2024-12-31 | $200.0K Ended 2024-12-31 | $683.0K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $9.16M Ended 2023-12-31 | $1.80M Ended 2023-12-31 | $488.0K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $15.62M Ended 2022-12-31 | n/a | $386.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $30.98M Ended 2021-12-31 | n/a | $359.0K Ended 2021-12-31 |